Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$0.91 ▼ -0.06
(-6.21%)
MKT CAP: $91.2M • VOL: 812.9K
52W L $1 52W H $3
ROARABLE / RQD
E • 30/100
PIOTROSKI
5 / 9
STXS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $32.4M | $26.9M | $26.8M |
| YoY Revenue Growth % | +20.3% | +0.5% | — |
| Gross Profit | $17.1M | $14.6M | — |
| Gross Margin % | 52.7% | 54.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$22.1M | -$24.7M | -$21.8M |
| Operating Margin % | -68.3% | -80.0% | -80.0% |
| Net Income (GAAP) | -$21.6M | -$24.0M | -$20.7M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$13.7M | -$8.5M | -$9.1M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$13.7M | -$8.5M | -$9.1M |
| FCF Margin % | -42.3% | -31.6% | -34.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $13.4M | $12.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $13.5M | $6.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR STXS.